argenx NV ADR
$ 828.35
2.36%
14 Apr - close price
- Market Cap 50,575,303,000 USD
- Current Price $ 828.35
- High / Low $ 835.21 / 814.50
- Stock P/E 41.29
- Book Value 118.34
- EPS 19.60
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.09 %
- ROE 0.20 %
- 52 Week High 934.62
- 52 Week Low 510.06
About
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Analyst Target Price
$1039.75
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-26 | 2025-10-30 | 2025-07-15 | 2025-05-07 | 2025-02-27 | 2024-10-31 | 2024-07-25 | 2024-05-09 | 2024-02-29 | 2023-10-31 | 2023-07-27 | 2023-05-07 |
| Reported EPS | 6.7945 | 5.18 | 3.2572 | 2.2732 | 0.7125 | 1.39 | 0.45 | -1.04 | -1.68 | -1.25 | -1.69 | -0.71 |
| Estimated EPS | 5.95 | 4.44 | -0.99 | 2.0546 | 1.6979 | 0.03 | -0.98 | -0.86 | -1.7 | -1.54 | -1.73 | -2.26 |
| Surprise | 0.8445 | 0.74 | 4.2472 | 0.2186 | -0.9854 | 1.36 | 1.43 | -0.18 | 0.02 | 0.29 | 0.04 | 1.55 |
| Surprise Percentage | 14.1933% | 16.6667% | 429.0101% | 10.6395% | -58.0364% | 4533.3333% | 145.9184% | -20.9302% | 1.1765% | 18.8312% | 2.3121% | 68.5841% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 5.25 |
| Currency | EUR |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ARGX
2026-04-14 20:09:31
This report analyzes Argenx SE, focusing on its lead therapy, Vyvgart, and its expansion into the U.S. rare disease market. It covers the company's business model, competitive landscape, growth catalysts, and risks, providing insights for U.S. and English-speaking market investors. The article highlights Vyvgart's potential for substantial revenue growth through new indications like CIDP and ongoing R&D in other autoimmune diseases.
2026-04-14 03:40:26
Argenx SE is positioned as a leader in immunology due to its proprietary therapy, Vyvgart, which generates strong revenue, particularly in the U.S. market. The company's strategic focus includes expanding Vyvgart's indications and developing a pipeline of other antibody-based therapies for autoimmune diseases. Despite competitive challenges and typical biotech risks, analysts maintain largely positive outlooks, citing the potential for continued growth fueled by U.S. sales and pipeline developments.
2026-04-10 11:09:19
RBC Capital has reaffirmed its Buy rating on Argenx Se (ARGX) with a price target of $890.00. Analyst Luca Issi, who covers the Healthcare sector, maintained this rating after the company reported strong quarterly revenues of $2.41 billion and a net profit of $874.92 million for the quarter ending December 31. Other analysts have also given varying ratings, including a Buy from Oppenheimer and a Hold from UBS.
2026-04-07 18:11:25
Argenx SE is a biotechnology company specializing in innovative antibody therapies for rare autoimmune diseases, with its lead product Vyvgart gaining market traction. The company utilizes a patented Natural Antibody Library technology for drug discovery and targets growth in the rare disease market through pipeline expansion and global partnerships. Investors are encouraged to assess Argenx's financial health, market position, and analyst perspectives against potential risks and their personal investment goals.
2026-04-07 18:10:20
Argenx SE specializes in innovative antibody therapies for rare autoimmune diseases, with its lead product, Vyvgart, already approved for conditions like generalized myasthenia gravis. The company demonstrates strong financial health and a robust R&D pipeline, making it an attractive option for investors interested in high-growth biotech. However, potential investors should monitor trial risks, regulatory delays, and emerging competition in the FcRn space.
2026-04-03 17:39:24
Argenx SE specializes in autoimmune disease treatments, with its lead product Vyvgart gaining market traction and strong financial performance. The company's innovative antibody platform positions it for potential long-term growth, attracting investor interest and favorable analyst ratings despite the inherent volatility and competitive risks in the biotech sector. Investors should weigh its pipeline potential and strong market position against risks like clinical trial failures and competition.
